Chronic-dose Safety and Efficacy Study of a Bronchodilator Inhaler in Pediatric Asthmatics
Status: | Completed |
---|---|
Conditions: | Asthma, Asthma |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 4 - 11 |
Updated: | 4/21/2016 |
Start Date: | July 2007 |
This study is designed to evaluate the repeat-dose safety and effectiveness of a
bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11
years with asthma. The dosing period lasts three weeks and starts following a three-week
run-in period.
bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11
years with asthma. The dosing period lasts three weeks and starts following a three-week
run-in period.
Inclusion Criteria:
- Persistent asthma of a minimum of six months duration that has been stable for at
least four weeks prior to screening
- Male and female children aged 4-11 years, inclusive, with predicted forced expiratory
volume in 1 second (FEV1) 60-90%
- Ability to perform spirometry
- Demonstrate 12% airways reversibility
Exclusion Criteria:
- Require continuous treatment with beta-blockers, monoamine oxidase inhibitors,
tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids
- Presence of any non-asthmatic clinically-significant acute or uncontrolled chronic
diseases
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials